抗栓治疗患者脑出血血肿扩大的风险与时机
该回顾性研究纳入2016年12月至2022年5月单中心连续319例自发性脑出血患者,排除手术清除者,用ABC/2法计算体积,血肿扩大定义为体积增加≥33%和/或≥6 mL。44%病前使用抗栓药,20%发生血肿扩大,中位时间10小时。多因素分析显示联合抗血小板+抗凝与血肿扩大独立相关(aOR 2.71),其他抗栓药无显著关联;Cox模型仅联合治疗显著增加扩大速率(aHR 2.33),且概率在发病后即刻最高。
要点
- 联合抗血小板+抗凝治疗者血肿扩大发生率38%(9/24),未使用者19%(56/295),aOR 2.71(95%CI 1.09-6.73,P=0.032)。
- Cox多因素校正入院NIHSS后,仅联合抗栓与血肿扩大速率增加独立相关(aHR 2.33,95%CI 1.14-4.75,P=0.020)。
- 血肿扩大中位时间为距最后正常时间10小时(IQR 7-21),联合抗栓者扩大概率在发病后即刻最高。
- 距最后正常时间每过1小时,血肿扩大 odds 降低2%(aOR 0.98,95%CI 0.97-0.99,P=0.038)。
- 阿司匹林、P2Y12抑制剂、华法林、口服Xa抑制剂、直接凝血酶抑制剂、全剂量肝素类单用均未显示与血肿扩大显著相关。
适用人群与场景
- 自发性脑出血患者,来自单中心综合卒中中心,2016年12月至2022年5月连续纳入。
- 排除接受手术清除血肿的患者。
- 病前使用抗栓药者占44%(141/319),包括阿司匹林、P2Y12抑制剂、联合抗血小板、华法林、口服Xa抑制剂、直接凝血酶抑制剂、全剂量肝素类、联合抗血小板+抗凝。
诊断标准与关键阈值
- 血肿扩大定义为ICH体积增加≥33%和/或≥6 mL。
- ICH体积采用ABC/2法计算。
- 血肿扩大时间从最后正常时间(LKN)起算,中位10小时(IQR 7-21)。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 联合抗血小板+抗凝治疗者发生血肿扩大的风险显著增高(aOR 2.71),需警惕早期扩大。
- 血肿扩大概率在发病后即刻最高,随时间推移下降(每延迟1小时aOR 0.98)。
研究设计与关键结果
- 回顾性单中心研究,319例自发性ICH患者,44%病前使用抗栓药,20%(65/319)发生血肿扩大,中位时间10小时(IQR 7-21)。
- 多因素logistic回归:联合抗血小板+抗凝与血肿扩大独立相关(9/24,38% vs 56/295,19%;aOR 2.71,95%CI 1.09-6.73,P=0.032);距LKN每增加1小时,血肿扩大odds降低2%(aOR 0.98,95%CI 0.97-0.99,P=0.038);其他抗栓药无显著关联。
- 多因素Cox分析校正入院NIHSS后,仅联合抗血小板+抗凝与血肿扩大速率增加相关(aHR 2.33,95%CI 1.14-4.75,P=0.020),发病后即刻概率最高。
证据类型、等级与局限
- 证据类型:回顾性单中心队列研究。
- 局限:单中心、回顾性设计、样本量319例、排除手术患者、未提及盲法或外部验证。
对床旁实践的改变
- 对联合使用抗血小板+抗凝的脑出血患者,应意识到血肿扩大风险约翻倍,尤其在发病后早期需密切监测。
- 其他抗栓药(如单用阿司匹林、华法林、口服Xa抑制剂等)未显示显著增加血肿扩大风险,但该结论来自单中心回顾性研究,不能据此排除其临床风险。
- 血肿扩大风险随时间推移下降,对发病后延迟就诊者,评估血肿扩大可能性需考虑时间因素。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The risk of intracerebral hemorrhage (ICH) hematoma expansion (HE) is highest in the first hours after onset, and coagulopathy is believed to further increase this risk. However, there is a paucity of data comparing the risk of HE over time for various antithrombotic agents.
METHODS: We conducted a retrospective study of spontaneous ICH patients enrolled at a comprehensive stroke center between December 2016 and May 2022, excluding those who underwent surgical evacuation. ICH volumes were calculated using ABC/2 methodology and HE was coded for a ≥ 33% and/or ≥ 6-mL increase in ICH volume. Multivariable logistic regression and Cox proportional hazards models were constructed to evaluate risk of HE among patients exposed to the following antithrombotics: aspirin, P2Y12 inhibitors, aspirin + P2Y12 inhibitors, warfarin, oral factor Xa inhibitors, direct thrombin inhibitors, full dose heparinoids, and combined antiplatelet + anticoagulant.
RESULTS: Of 319 patients with ICH, 141 (44%) were on an antithrombotic at the time of ICH and 65 (20%) had HE in a median of 10 h (interquartile range (IQR) 7-21) from last known normal (LKN). In multivariable logistic regression analyses, the odds of HE decreased by 2% for every hour from LKN (adjusted odds ratio (aOR) 0.98, 95% CI 0.97-0.99, P = 0.038), and HE occurred significantly more often in patients taking combined antiplatelet + anticoagulant (9/24, 38%) compared with those who were not (56/295, 19%, aOR 2.71, 95% CI 1.09-6.73, P = 0.032). No other antithrombotic was significantly associated with HE. In multivariable Cox analysis adjusting for admission National Institutes of Health Stroke Scale (NIHSS), only antiplatelet + anticoagulant use was associated with significantly increased rates of HE (adjusted HR (aHR) 2.33, 95% CI 1.14-4.75, P = 0.020), with the highest probability of HE occurring immediately after ICH onset.
CONCLUSIONS: Use of combined antiplatelet + anticoagulant was associated with a twofold increased hazard of HE, with the highest probability of expansion occurring early after ICH onset. No increased rate of HE was observed for other antithrombotics.
参考来源
- Frontera JA, Marmo JM, Gummadi B, et al. Risk and Timing of Intracerebral Hemorrhage Expansion Among Patients Treated with Antithrombotic Agents. Neurocrit Care. 2026. PMID: 42477256. doi:10.1007/s12028-026-02581-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。